CTDHoldings 24st Centry Investments Cydodextrins
  • Home
  • Company Info
    • Overview
    • Management Team
    • Board of Directors
    • Mission & Vision
  • Cyclodextrins
    • Trappsol® Cyclo™
    • Trappsol®
    • Aquaplex®
    • Applications
  • Subsidiaries
    • CTD, Inc.
  • Our Business
    • Cyclodextrin Market
  • Media Center
    • Company News
    • Selected Articles
  • Investors
    • News / Events
      • Company News
      • In The News
      • Selected Articles
      • Presentations
      • Email Alerts
    • Company Information
      • Profile
      • Management Team
      • IR Contacts
      • FAQ
    • Financial Information
      • Financials
    • Stock Information
      • Quote
      • Charts
      • Historical Quotes
    • SEC Filings
      • All SEC Filings
      • Insiders
    • Corporate Governance
      • Board of Directors
      • Governance Documents
  • Contact Us
 

Selected Articles

  • Home
  • Investors
  • News / Events
  • Selected Articles
  • Niemann-Pick disease type C
  • A novel, highly sensitive and specific biomarker for Niemann-Pick type C1 disease
  • P352 - Use of Cyclodextrin in two Brazilian Girls with Niemann-Pick Disease Type C
  • High Incidence of Unrecognized Visceral/Neurological Late- onset Niemann-Pick Disease, type C1 Predicted by Analysis of Massively Parallel Sequencing Data Sets
  • Linear Clinical Progression, Independent of Age of Onset, in Niemann-Pick Disease, type C
  • Cyclodextrin alleviates neuronal storage of cholesterol in Niemann-Pick C disease without evidence of detectable blood–brain barrier permeability
  • Pulmonary involvement in Niemann-Pick C type 1
  • Niemann-Pick C disease and mobilization of lysosomal cholesterol by cyclodextrin
  • Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease
  • Therapeutic potential of cyclodextrins in the treatment of Niemann–Pick type C disease
  • Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1-/- mouse
  • Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases
  • News / Events
    • Company News
    • In The News
    • Selected Articles
    • Presentations
    • Email Alerts
  • Company Information
  • Financial Information
  • Stock Information
  • SEC Filings
  • Corporate Governance

Links

  • Home
  • Cyclodex
  • Disclaimer
  • Privacy Policy
  • Terms & Conditions
  • Sitemap
  • Contact Us

Investor Quicklinks

  • image description
    IR Overview
  • image description
    IR Contacts
  • image description
    IR FAQ
  • image description
    News/Events
  • image description
    Financial Info
  • image description
    SEC Filing
  • image description
    Corporate Governance
  • image description
    Stock Info

Connect With Us

  • rss
  • youtube
  • mail
© Copyright 2021 Cyclo Therapeutics, Inc. All Rights Reserved. Website by Equisolve